Published in Cancer Res on April 14, 2009
Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas. Nat Neurosci (2011) 1.84
Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. Cold Spring Harb Perspect Med (2012) 1.68
The thrombospondins. Cold Spring Harb Perspect Biol (2011) 1.52
Thrombospondins function as regulators of angiogenesis. J Cell Commun Signal (2009) 1.40
A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model. Mol Cancer Ther (2010) 1.34
Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level. FASEB J (2009) 1.29
Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways. Cell Death Dis (2014) 0.96
Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer. BMC Cancer (2012) 0.94
Lysophosphatidic acid suppresses endothelial cell CD36 expression and promotes angiogenesis via a PKD-1-dependent signaling pathway. Blood (2011) 0.94
Antiangiogenic variant of TSP-1 targets tumor cells in glioblastomas. Mol Ther (2014) 0.84
Original insights on thrombospondin-1-related antireceptor strategies in cancer. Front Pharmacol (2015) 0.82
Thrombospondin-1 type 1 repeats in a model of inflammatory bowel disease: transcript profile and therapeutic effects. PLoS One (2012) 0.80
Protein Kinase D1 Signaling in Angiogenic Gene Expression and VEGF-Mediated Angiogenesis. Front Cell Dev Biol (2016) 0.80
Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization. Adv Drug Deliv Rev (2016) 0.79
LPA/PKD-1-FoxO1 Signaling Axis Mediates Endothelial Cell CD36 Transcriptional Repression and Proangiogenic and Proarteriogenic Reprogramming. Arterioscler Thromb Vasc Biol (2016) 0.76
Diet-induced obesity links to ER positive breast cancer progression via LPA/PKD-1-CD36 signaling-mediated microvascular remodeling. Oncotarget (2017) 0.75
Cell death: critical control points. Cell (2004) 22.56
Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science (2002) 14.50
Two CD95 (APO-1/Fas) signaling pathways. EMBO J (1998) 10.42
Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem (1998) 8.30
Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med (1995) 7.88
Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol (2002) 7.76
Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene (2006) 6.61
Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer (2005) 5.65
Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med (2000) 5.05
The structure of human thrombospondin, an adhesive glycoprotein with multiple calcium-binding sites and homologies with several different proteins. J Cell Biol (1986) 4.16
Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem (1998) 3.78
Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J Biol Chem (1999) 3.76
CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol (1997) 3.52
Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell (2007) 3.37
Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol (1999) 3.15
Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol (1993) 3.15
SH3 domains direct cellular localization of signaling molecules. Cell (1993) 2.73
The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev (2003) 2.66
Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiat Res (2003) 2.49
Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med (2002) 2.34
The role of thrombospondins 1 and 2 in the regulation of cell-matrix interactions, collagen fibril formation, and the response to injury. Int J Biochem Cell Biol (2004) 2.01
Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis. Curr Opin Immunol (1998) 1.96
Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res (1997) 1.81
A simple immunomagnetic protocol for the selective isolation and long-term culture of human dermal microvascular endothelial cells. Exp Cell Res (1998) 1.81
Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor. Proc Natl Acad Sci U S A (2003) 1.80
Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol (2003) 1.76
Regulation of tumor angiogenesis by thrombospondin-1. Biochim Biophys Acta (2005) 1.76
NK cells and cancer. J Immunol (2007) 1.56
Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms. Cancer Res (2001) 1.56
Cell surface Death Receptor signaling in normal and cancer cells. Semin Cancer Biol (2003) 1.54
Thrombospondin-1 induces endothelial cell apoptosis and inhibits angiogenesis by activating the caspase death pathway. J Vasc Res (2000) 1.42
Apoptotic cues from the extracellular matrix: regulators of angiogenesis. Oncogene (2003) 1.41
Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. Int J Cancer (2002) 1.37
TRAIL: a multifunctional cytokine. Front Biosci (2007) 1.34
Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors. Semin Cancer Biol (2004) 1.21
Clearing the TRAIL for Cancer Therapy. Cancer Cell (2007) 1.13
Targeting TRAIL agonistic receptors for cancer therapy. Clin Cancer Res (2007) 1.10
In vivo upregulation of CD95 and CD95L causes synergistic inhibition of angiogenesis by TSP1 peptide and metronomic doxorubicin treatment. Cell Death Differ (2005) 1.08
Death receptor signals to mitochondria. Cancer Biol Ther (2004) 1.07
The complexity of TNF-related apoptosis-inducing ligand. Ann N Y Acad Sci (2000) 0.96
Antiangiogenic treatment with the three thrombospondin-1 type 1 repeats recombinant protein in an orthotopic human pancreatic cancer model. Clin Cancer Res (2005) 0.92
Modulation of TRAIL-induced tumor cell apoptosis in a hypoxic environment. Cancer Biol Ther (2005) 0.89
Transduction of tumor necrosis factor-related apoptosis-inducing ligand into hematopoietic cells leads to inhibition of syngeneic tumor growth in vivo. Cancer Res (2006) 0.85
Analysis of TNF-related apoptosis-inducing ligand in vivo through bone marrow transduction and transplantation. Methods Enzymol (2008) 0.84
Expression of the thrombospondin 1 receptor CD36 is correlated with decreased stromal vascularisation in colon cancer. Int J Oncol (1999) 0.82
Insights into the mitochondrial signaling pathway: what lessons for chemotherapy? J Clin Immunol (2003) 0.81
Multifaceted targeting in cancer: the recent cell death players meet the usual oncogene suspects. Expert Opin Ther Targets (2007) 0.79
Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res (2003) 14.79
Stepwise reprogramming of B cells into macrophages. Cell (2004) 7.68
Thrombospondins are astrocyte-secreted proteins that promote CNS synaptogenesis. Cell (2005) 7.41
Myeloid or lymphoid promiscuity as a critical step in hematopoietic lineage commitment. Dev Cell (2002) 4.37
Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell (2005) 3.74
Gabapentin receptor alpha2delta-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell (2009) 3.46
In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction. Proc Natl Acad Sci U S A (2013) 3.10
The thrombospondins. Int J Biochem Cell Biol (2004) 3.01
Crystal structure of the TSP-1 type 1 repeats: a novel layered fold and its biological implication. J Cell Biol (2002) 2.28
The lack of thrombospondin-1 (TSP1) dictates the course of wound healing in double-TSP1/TSP2-null mice. Am J Pathol (2002) 2.22
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A (2003) 2.20
In vivo generation of transplantable human hematopoietic cells from induced pluripotent stem cells. Blood (2012) 2.12
Critical role of endogenous thrombospondin-1 in preventing expansion of healing myocardial infarcts. Circulation (2005) 2.09
B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci U S A (2010) 2.03
Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med (2014) 2.01
Sox4 is a key oncogenic target in C/EBPα mutant acute myeloid leukemia. Cancer Cell (2013) 1.89
Risk factors for severe illness with 2009 pandemic influenza A (H1N1) virus infection in China. Clin Infect Dis (2011) 1.87
Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor. Proc Natl Acad Sci U S A (2003) 1.80
Regulation of tumor angiogenesis by thrombospondin-1. Biochim Biophys Acta (2005) 1.76
Preoperative evaluation of thyroid nodules with 18FDG-PET/CT. Surgery (2005) 1.76
Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. Cold Spring Harb Perspect Med (2012) 1.68
Activation of DegP chaperone-protease via formation of large cage-like oligomers upon binding to substrate proteins. Proc Natl Acad Sci U S A (2008) 1.68
Inhibition of Tie-2 signaling induces endothelial cell apoptosis, decreases Akt signaling, and induces endothelial cell expression of the endogenous anti-angiogenic molecule, thrombospondin-1. Cancer Biol Ther (2004) 1.62
Chemical analysis of the Chinese herbal medicine Gan-Cao (licorice). J Chromatogr A (2008) 1.60
Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins. J Cell Biol (2005) 1.59
Thrombospondin-1-deficient mice exhibit increased vascular density during retinal vascular development and are less sensitive to hyperoxia-mediated vessel obliteration. Dev Dyn (2003) 1.53
A novel orthotopic mouse model of human anaplastic thyroid carcinoma. Thyroid (2009) 1.53
Endosomal compartment contributes to the propagation of CD95/Fas-mediated signals in type II cells. Biochem J (2008) 1.53
The thrombospondins. Cold Spring Harb Perspect Biol (2011) 1.52
Bortezomib treatment causes remission in a Ph+ALL patient and reveals FoxO as a theranostic marker. Cancer Biol Ther (2011) 1.51
Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc Natl Acad Sci U S A (2005) 1.51
SNP rs356219 of the α-synuclein (SNCA) gene is associated with Parkinson's disease in a Chinese Han population. Parkinsonism Relat Disord (2012) 1.49
BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. Cancer Res (2011) 1.47
A thrombospondin-dependent pathway for a protective ER stress response. Cell (2012) 1.45
Diversity of the protein disulfide isomerase family: identification of breast tumor induced Hag2 and Hag3 as novel members of the protein family. Mol Phylogenet Evol (2005) 1.44
The heterogeneity of non-motor symptoms of Parkinson's disease. Neurol Sci (2014) 1.42
Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res (2004) 1.42
Carcinoid tumors in the breast. Am J Surg (2006) 1.41
Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis. Invest Ophthalmol Vis Sci (2004) 1.40
Cartilage oligomeric matrix protein/thrombospondin 5 supports chondrocyte attachment through interaction with integrins. J Biol Chem (2005) 1.37
Knowledge, attitudes and practices (KAP) relating to avian influenza in urban and rural areas of China. BMC Infect Dis (2010) 1.36
Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)endothelial VWF from cleavage by ADAMTS13. Blood (2005) 1.35
Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP-1). J Cell Physiol (2007) 1.35
Microbial transformation of ginsenoside Rb1 by Rhizopus stolonifer and Curvularia lunata. Biotechnol Lett (2003) 1.33
Neuropilin-1 modulates p53/caspases axis to promote endothelial cell survival. PLoS One (2007) 1.32
The effect of thrombospondin-1 on breast cancer metastasis. Breast Cancer Res Treat (2008) 1.32
Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer. Clin Cancer Res (2004) 1.31
Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level. FASEB J (2009) 1.29
Protein phosphatase 2A reactivates FOXO3a through a dynamic interplay with 14-3-3 and AKT. Mol Biol Cell (2010) 1.29
Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Res (2004) 1.28
Cloning and characterization of PAK5, a novel member of mammalian p21-activated kinase-II subfamily that is predominantly expressed in brain. Oncogene (2002) 1.27
Interaction of cartilage oligomeric matrix protein/thrombospondin 5 with aggrecan. J Biol Chem (2007) 1.27
Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist (2011) 1.27
Thrombospondin-based antiangiogenic therapy. Microvasc Res (2007) 1.26
Structural basis for conformational dynamics of GTP-bound Ras protein. J Biol Chem (2010) 1.26
CDIP, a novel pro-apoptotic gene, regulates TNFalpha-mediated apoptosis in a p53-dependent manner. EMBO J (2007) 1.25
The structures of the thrombospondin-1 N-terminal domain and its complex with a synthetic pentameric heparin. Structure (2006) 1.25
AACE/ACE disease state commentary: molecular diagnostic testing of thyroid nodules with indeterminate cytopathology. Endocr Pract (2014) 1.24
Apoptotic cell signaling in cancer progression and therapy. Integr Biol (Camb) (2011) 1.22
Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumonia. Antimicrob Agents Chemother (2002) 1.20
Identification of novel beta1 integrin binding sites in the type 1 and type 2 repeats of thrombospondin-1. J Biol Chem (2004) 1.19
SCF(β-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2. J Exp Med (2012) 1.18
Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E). Biochim Biophys Acta (2009) 1.18
Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL) Receptor-1 and Receptor-2 agonists for cancer therapy. Expert Opin Biol Ther (2010) 1.17
Skeletal abnormalities in mice lacking extracellular matrix proteins, thrombospondin-1, thrombospondin-3, thrombospondin-5, and type IX collagen. Am J Pathol (2008) 1.17
Improved vascular engraftment and graft function after inhibition of the angiostatic factor thrombospondin-1 in mouse pancreatic islets. Diabetes (2008) 1.17
Thrombospondin-1 is an endogenous activator of TGF-beta in experimental diabetic nephropathy in vivo. Diabetes (2007) 1.15
Apoptotic pathways in tumor progression and therapy. Adv Exp Med Biol (2008) 1.15
C/EBPγ deregulation results in differentiation arrest in acute myeloid leukemia. J Clin Invest (2012) 1.14
Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors. Cancer Res (2009) 1.14
Endogenous thrombospondin-1 is not necessary for proliferation but is permissive for vascular smooth muscle cell responses to platelet-derived growth factor. Matrix Biol (2005) 1.14
Counterbalancing angiogenic regulatory factors control the rate of cancer progression and survival in a stage-specific manner. Proc Natl Acad Sci U S A (2011) 1.13
FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis. Biochim Biophys Acta (2007) 1.13
Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer. Endocrinology (2011) 1.13
Travel patterns in China. PLoS One (2011) 1.12
Thrombospondin 1 inhibits inflammatory lymphangiogenesis by CD36 ligation on monocytes. J Exp Med (2011) 1.10
Activation of vascular endothelial growth factor receptor-3 and its downstream signaling promote cell survival under oxidative stress. J Biol Chem (2004) 1.10
Phytochemical analysis of traditional Chinese medicine using liquid chromatography coupled with mass spectrometry. J Chromatogr A (2008) 1.10
Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2. Clin Cancer Res (2005) 1.09
c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells. Cancer Res (2007) 1.09
Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels. Cancer Res (2007) 1.09
Sustained PU.1 levels balance cell-cycle regulators to prevent exhaustion of adult hematopoietic stem cells. Mol Cell (2013) 1.09
TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors. Clin Cancer Res (2010) 1.08
Tanshinones: sources, pharmacokinetics and anti-cancer activities. Int J Mol Sci (2012) 1.08